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ABSTRACT 
Background. Patients with end-stage kidney disease (ESKD) are at increased risk premature 
death, with cardiovascular disease being the predominant mode of death. We hypothesized 
that left ventricular global longitudinal strain (LV-GLS) measured by feature tracking 
cardiovascular magnetic resonance imaging (CMR) would be associated with all-cause 
mortality in patients with ESKD. 
Methods. A pooled analysis of CMR studies in patients with ESKD acquired within a single 
centre between 2002 and 2016 was carried out. CMR parameters including left ventricular 
ejection fraction (LVEF), LV mass index (LVMI), left atrial emptying fraction (LAEF) and LV-
GLS were measured. We tested independent associations of CMR parameters with survival 
using a multivariable Cox model. 
Results. Among 215 patients (mean age: 54 years, 62% male), mortality was 53% over 5.0 
years median follow-up. The median LVEF was 64.7% (IQR 58.5, 70.0) and median LV-GLS 
was -15.3% (-17.24, -13.6). While 90% of patients had preserved LVEF (>50%), 58% of this 
group had abnormal LVGLS (>-16%). On multivariable Cox regression, age (HR: 1.04, 95%CI: 
1.02-1.05), future-renal transplant (HR 0.29 95%CI: 0.17-0.47), LAEF (HR: 0.98, 95%CI: 0.96-
1.00) and LV-GLS (HR: 1.08, 95%CI: 1.01-1.16) were independently associated with mortality. 
Conclusions. In this cohort of patients with ESKD, LV-GLS on feature tracking CMR and 
LAEF were associated with all-cause mortality, independent of baseline clinical variables and 
future renal transplantation. This effect was present even when >90% of the cohort had normal 
left ventricular ejection fraction (LVEF). Using LV-GLS, instead of LVEF, to diagnose cardiac 
dysfunction in patients with ESKD could result in a major advance in our understanding of 
cardiovascular disease in ESKD. 
Keywords: cardiovascular, chronic renal failure, ESKD, left ventricular hypertrophy, magnetic 
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KEY LEARNING POINTS
What is already known about this subject?
 Left ventricular global longitudinal strain (LV-GLS) measures percentage muscle 
deformation during the cardiac cycle as a sensitive marker of myocardial function. 
 LV-GLS measured on echocardiography is known to associate with mortality in 
patients with end-stage kidney disease (ESKD). The association of LV-GLS on 
cardiovascular MRI and survival has not been studied in patients with ESKD. 
What this study adds?
 LV-GLS on cardiovascular MRI was associated with all-cause mortality, independent 
of baseline clinical variables and future renal transplantation. 
 This effect was present even when >90% of the cohort had normal left ventricular 
ejection fraction (LVEF). 
 The survival benefit of renal transplantation was evident even in the quartile of 
participants with the most severely impaired LV-GLS. 
What impact this may have on practice or policy?
 Using LV-GLS, instead of LVEF, to diagnose cardiac dysfunction in patients with 
ESKD could result in a major advance in our understanding of cardiovascular 
disease and prognosis in ESKD
 LV-GLS in isolation is unlikely to be helpful when assessing an individual’s suitability 
for renal transplantation.
 Further studies exploring cardiovascular therapeutics in patients with ESKD who 
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INTRODUCTION
Patients with chronic kidney disease (CKD) are at increased risk of death from all-causes 
compared to the general population (1). The majority of this increased risk is due to 
cardiovascular disease (2). While ischaemic heart disease is the most common form of 
cardiovascular disease in the general population, patients with CKD have relatively fewer 
atherosclerotic events but a disproportionate increase in the risk of sudden cardiac death and 
death from arrhythmogenic causes (3). This risk increases with severity of CKD (2), such that 
patients with CKD stage 5 are 3-4 times more likely to experience a cardiovascular event than 
age-standardized patients without CKD (4).This excess cardiovascular risk is intrinsically 
linked to cardiac structural and functional abnormalities, which start to develop early in CKD 
(5). These include left ventricular hypertrophy (LVH), cardiac dysfunction and myocardial 
fibrosis, which together are sometimes referred to as a ‘uraemic cardiomyopathy’ (6–8). The 
utility of cardiac magnetic resonance (CMR) imaging to detect these abnormalities has been 
an area of growing interest and CMR may prove to be a useful tool in the development of non-
invasive novel biomarkers for future risk-stratification (9,10). 
Left ventricular global longitudinal strain (LV-GLS) measures percentage muscle deformation 
during the cardiac cycle as a sensitive marker of myocardial function [(11). Feature tracking 
CMR is a non-contrast post-processing technique that derives LV-GLS by tracking endo- and 
epicardial borders through successive images from routinely acquired cine CMR sequences 
(11). Normal values for LV-GLS measured by feature tracking CMR are approximately -20 +/- 
4%(12–14).  LV-GLS has been shown to be a strong correlate of mortality and clinical 
outcomes in patients with myocardial infarction (15), and improvements in LV-GLS have been 
reported following renal transplantation (16). In patients with CKD, utilizing echocardiography, 
GLS has been reported to predict clinical outcomes (17). However, CMR is considered the 
gold standard imaging modality in end-stage kidney disease (ESKD), as fluctations in volume 
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We hypothesised that LV-GLS on feature tracking CMR has incremental prognostic utility over 




CMRs from research studies carried out in participants with ESKD within a regional renal and 
transplant centre between 2002 and 2016 were pooled. Patients for whom CMR images were 
available and who had consented for long term data follow-up were eligible for inclusion. All 
participants had CKD stage 5 (eGFR <15 ml/min/1.73m2) and were receiving, or estimated to 
be within 6 months of requiring, renal replacement therapy. Further details of the cohorts are 
described elsewhere (ClinicallTrials.gov ID NCT01951404) (19–21). Participants provided 
written informed consent and regional ethics committee approval was granted; the study was 
conducted in agreement with the Declaration of Helsinki.
Clinical data were manually collected via the West of Scotland Electronic Renal Patient Record 
database (Vitalpulse, Chelmsford, UK) by members of the team blinded to other aspects of 
the study. Baseline clinical variables included demographic characteristics and medical 
history. The primary outcome was all-cause mortality. The secondary outcome was 
cardiovascular mortality defined as death due to myocardial infarction, heart failure, sudden 
cardiac death, stroke and peripheral vascular disease (22). 
CMR Image Acquisition 
CMR acquisition was performed using 1.5 Tesla (T) (Sonata, Siemens Erlangen, Germany) 
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patients on haemodialysis, the scans were performed 24 hours following the end of their 
dialysis session. Imaging protocols were similar in all studies and were as described previously 
(19–21). In short, electrocardiograph-gating was used and the images were acquired in end-
expiration. Following the acquisition of localiser images, balanced steady state free precession 
sequences were used to acquire left ventricular cines in three long axis planes, followed by a 
short axis stack from the apex to the atrio-ventricular ring. Additional details are available in 
supplementary materials S1. 
CMR Image Analysis
All data analysis was carried out in a core lab, utilizing dedicated CMR software (cvi42 
software (version 5.10, Circle Cardiovascular, Canada)). Routinely analysed CMR measures 
of left ventricular (LV) and right ventricular (RV) function were carried out according to current 
guidelines (23), with parameters of myocardial mass and ventricular volumes derived from the 
short-axis views and indexed to body surface area.  Ventricular endocardial and epicardial 
contours were manually drawn at end-diastole. Left ventricular endocardial contours were 
drawn at end-systole, which was deemed to be the phase with the smallest blood pool cavity.  
Papillary muscles were excluded from myocardial mass and included in volumes. For the 
purposes of strain measurements, the manually drawn ventricular contours were propagated 
throughout the cardiac cycle using the software’s machine-learning algorithms. Automated 
contours were individually checked and corrected, where necessary. Global left ventricular 
strain (circumferential, longitudinal, and radial) and global right ventricular strain (longitudinal 
and radial) were derived using the tissue tracking module to derive values of peak strain and 
strain graphs following the manufacturer’s advised standard protocols (Figure 1). Atrial 
volumes were indexed to body surface area and derived from automated contours, with 
manual correction as needed. Left atrial emptying fraction (LAEF) was calculated as the 
percentage difference between maximal and minimal left atrial volume divided by maximal 
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second independent observer (AJR) analysed a random sample of >10% of the cohort to 
assess inter-observer variability. Both observers were blinded to clinical outcomes.
Statistical Analysis
Continuous data with a normal distribution are presented as mean ± standard deviation (SD), 
and median and interquartile range (IQR) for skewed data, with normality defined according 
to Shapiro-Wilk test. Exploratory analyses using independent Student’s t-tests, Mann Whitney 
U test, and Pearson’s Chi-squared test, as appropriate, were performed on baseline variables 
of clinical significance. Kruskal-Wallis test was used to compare LV-GLS by year of scan. 
Univariable Cox proportional hazards analysis was performed to identify CMR variables 
associated with outcome. Parameters that were significantly associated with outcome were 
then entered into a model including pre-specified baseline clinical variables of age, sex, 
diabetes, heart failure, and previous myocardial infarction. Future renal transplantation was 
added to the model as a time-dependant covariate. The proportional hazards assumption was 
tested for continuous variables using Schoenfeld’s residuals and deemed satisfied when the 
p value was >0.05. A backwards stepwise regression model using Wald’s statistic was 
performed with an exclusion threshold of p > 0.1. An assessment of model fit was not 
performed due to the necessary inclusion of future renal transplantation as a time-dependent 
covariate. CMR variables of independent significance in the multivariable model were divided 
into quartiles and compared using Kaplan-Meier survival analysis and the log-rank test, 
including sub-group analyses based on future renal transplantation. Intra- and interobserver 
variability was assessed by the intra-class correlation (ICC) coefficient (two-way mixed effect, 
average measures). Receiver-operator curve analysis was used to identify an optimal 
prognostic threshold for LV-GLS. Statistical analysis was performed using SPSS (version 26, 
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RESULTS
Participant characteristics
A total of 215 patients were included (144 of whom were being considered for renal 
transplant(19,21), and 71 incident dialysis patients without overt heart failure (33 from 
Rutherford et al (20) and 38 locally acquired baseline scans from a recent trial of allopurinol 
therapy in dialysis patients (ClinicallTrials.gov ID NCT01951404)). There was no difference in 
survival or LV-GLS by year of scan (log rank test p=0.99, and Kruskal Wallis test H=2.77, 
p=0.60, respectively). 
In total, 133 (62%) were male and mean age was 54.0 ± 12.1 years (Table 1). The majority of 
participants were white (200; 93%), with 11 Asian, 3 black and 1 other. At the time of scanning, 
181 (84%) patients were receiving renal replacement therapy, of whom 8 (4%) had a 
functioning renal transplant (median eGFR 10.5 (IQR 9.1 - 13.3) ml/min/1.73m2). The 
remaining 34 (16%) patients had CKD stage 5 with median eGFR 10.4 (IQR 8.6 - 12.8) 
ml/min/1.73m2. During a median follow-up of 5.0 years (range 1 day – 16.9 years), there were 
115 deaths (53%). Specific cause of death was available for 96 (83%) patients and included 
34 (35%) due to infection, 33 (34%) cardiovascular (22 cardiac, 9 peripheral vascular disease, 
4 stroke), 13 (14%) cancer, 7 (7%) withdrawal of dialysis, and 9 (9%) other causes. 
Participants who survived were younger (51.6 +/- 11.7 versus 56.2 +/-12.2 years, p = 0.005), 
with similar sex distribution and body mass index (Table 1). Deceased patients were 
significantly more likely to have diabetes at baseline (37% vs 22%, p = 0.014), however history 
of cardiac disease including myocardial infarction and heart failure were similar (table 1). 
Table 2 summarises the CMR results for the cohort. Seven patients had reduced left 
ventricular ejection fraction (LVEF) <40%, while a further 14 patients had mid-range ejection 
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(24,25). One hundred twelve patients with preserved LVEF >50% had abnormal LV-GLS when 
defined as >-16.0% (12). Intra-and inter observer reproducibility were excellent for left atrial 
(LA), right atrial (RA) and LV parameters (ICC >0.92) and moderate for RV parameters (ICC 
0.57-0.74) (Supplementary material table S2) (26).
CMR parameters and All-cause Mortality
On univariable analysis with each variable entered separately, LV-GLS, LV-GRS, RV-GLS, 
RV-GRS, minimum left atrial volume and LAEF were significantly associated with all-cause 
mortality (Table 3). A multivariable model was created of these variables combined with the 
pre-specified clinical variables of gender, age, diabetes, heart failure, previous MI and future 
renal transplant. Following backwards stepwise elimination, LV-GLS and LAEF were the only 
CMR parameters that remained independently associated with mortality, in combination with 
gender, age, and future renal transplantation (Table 3). All other variables were excluded.
Patients were divided into quartiles according to LV-GLS and LAEF. The quartiles for LV-GLS 
are as follows: first quartile < -17.24% (best), second quartile -17.25% to -15.28%, third 
quartile -15.29 to -13.62%, fourth quartile > -13.61% (worst). The quartiles for LAEF were: first 
quartile <50.12 % (worst), second quartile 50.13-57.30%, third quartile 57.31-64.94%, and 
fourth quartile >64.94% (best). Compared to the best quartile of LV-GLS, participants in the 
worst quartile had significantly poorer outcomes (p=0.03, Figure 2), with no difference between 
the other quartiles. Similarly, the first quartile of LAEF had significantly worse survival 
compared to participants in the 3rd and 4th quartiles of LAEF (Figure 2, p= 0.003 and 0.03). 
On receiver-operator curve (ROC) analysis, there was no single threshold of LV-GLS with 
meaningful prognostic value for all-cause mortality. When 1 -year mortality was examined, the 
area under the curve (AUC) for LV-GLS was 0.71 from which a LV-GLS cut-off of -14.1% 
would yield 77% sensitivity and 67% specificity. However, when 2-year mortality was 
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LV-GLS differed by sex within the cohort, with females having greater contractility than males 
(median GLS -16.17% (females) vs -14.52% (males); Mann-Whitney U test p<0.001). There was 
no difference in mortality by sex (log rank p=0.48). When only female patients were studied, LV-
GLS was significantly associated with all-cause mortality (HR 1.21 (1.08-1.35, p=0.001) but the 
association was not detected when only male patients were studied (HR 1.08 (-.99-1.18, p=0.09)). 
There was no difference in LAEF by sex (Mann Whitney U test p=0.15).
CMR parameters and Cardiovascular mortality
With regards the secondary outcome of cardiovascular mortality, LV-GLS (HR 1.17 (95% CI: 
1.00-1.25)) and LAEF (HR 0.949 (95% CI: 0.92-0.98)) were the only CMR parameters that 
significantly associated with outcome on univariable analysis. Following backwards 
elimination, LAEF was the only CMR parameter that remained significantly associated with 
cardiovascular mortality in the multivariable model containing age: HR 1.08 (95% CI: 1.04-
1.12); diabetes: HR 2.30 (95% CI: 1.12-4.71); future renal transplant: HR 0.35 (95% CI: 0.13-
0.95); LAEF: HR 0.96 (95% CI: 0.93-0.99).
CMR parameters and future Renal Transplantation
A total of 106 (49%) of patients received a renal transplant during the follow-up. Of these, 33 
patients died. Patients who received a transplant had lower median LV-GLS than those who 
did not (-15.63% (-17.32 - -14.18) compared to -14.88% (-16.82- -13.08) p=0.04). There was 
no difference in LAEF between those who did and did not receive a future renal transplant 
(p=0.10). The survival benefit of renal transplantation was evident on Kaplan-Meier survival 
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DISCUSSION
This large, retrospective study of CMR in patients with ESKD found that LV-GLS by feature 
tracking CMR and LAEF have significant association with all-cause mortality, independent of 
baseline clinical variables and future renal transplantation. Importantly, these associations 
were present even when the majority of the cohort had normal cardiac function as defined by 
traditional parameters (i.e. LVEF).
Benefits of Using Feature Tracking CMR for Strain Analysis
CMR is the gold standard for the assessment of cardiac volumes and mass in patients with 
renal failure (10,18). Although strain imaging by echocardiography is likely to be more 
accessible, it can be limited by poor availability of acoustic windows, image quality, expertise 
required and inter-operator variability. Fluid shifts associated with dialysis may further impair 
the accuracy and reliability of this measure. The ability to quantify LV-GLS accurately and 
quickly using CMR supports the superiority of CMR over echocardiography. Feature tracking 
is a technique that measures strain using routinely acquired steady state free procession 
(SSFP) sequences and obviates the need for acquisition of bespoke CMR strain sequences 
such as myocardial tagging. Feature tracking strain has been validated against myocardial 
tagging (27,28) with the additional advantage that it is able to generate this data in less than 
a quarter of the time needed by tagging. We believe feature tracking CMR is at the intersection 
of accuracy and ease of acquisition and have demonstrated its utility in this cohort. 
Global Longitudinal Strain as a Predictor of Mortality and Cardiac Dysfunction
In patients with CKD, LV-GLS measured by echocardiography has consistently been shown 
to be an independent predictor of mortality. Associations have been demonstrated in patients 
with CKD stage 3B-5D (17), CKD stage 4-5D (29), and patients on dialysis (30). LV-GLS has 
theoretical advantages over LVEF for the assessment of cardiac function in patients with CKD: 
reduced LVEF has been shown to occur late in the development of the uraemic 
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preserved ejection fraction in ESKD populations (32). This is likely explained by the differential 
aspects of myocardial function that the 2 techniques measure. While LVEF simply assesses 
the difference in volume at end diastole and systole, LV-GLS assesses the function of 
subendocardial fibres, which more directly correlates to the extent of interstitial myocardial 
fibrosis (30). In our study, 112 (58%) of 194 patients with preserved LVEF (>50%) had 
abnormal LV-GLS when defined as >-16% (a threshold chosen based on the normal LV-GLS 
in healthy subjects being -20% +/-4% (12–14)). This may partly explain the extreme 
cardiovascular risk seen in ESKD populations, despite relatively low prevalence of heart failure. 
Accordingly, there would be an argument to investigate cardiovascular therapeutics, 
especially those with anti-fibrotic properties (such as mineralocorticoid receptor antagonists) 
in patients with ESKD who have impaired LV-GLS. Mineralocorticoid receptor antagonists 
have previously been studied in ESKD populations with no effect on LVMI but LV-GLS was 
not assessed (33,34). Given the high prevalence of impaired LV-GLS in ESKD populations, 
and the expected high frequency of events, we believe these trials would be of significant 
interest.  The difference in LV-GLS between men and women is well recognised (14). Sex was 
accounted for in the multivariable model which found LV-GLS to independently associated 
with mortality, nevertheless our subgroup analysis suggests a greater prognostic ability of LV-
GLS in women, compared to men, and this requires further study. The lack of association 
between LVEF and mortality in this cohort is likely explained by the low prevalence of reduced 
LVEF resulting in reduced statistical power. This is partly due to the entry criteria of the pooled 
studies which excluded patients with known severe left ventricular systolic dysfunction. On the 
contrary, the fact that LV-GLS associated with mortality, even when the vast majority of 
patients did not have heart failure, is striking. The lack of clear threshold of LV-GLS in 
predicting mortality on the ROC analysis suggests that LV-GLS alone is unlikely to be a useful 
prognostic tool, albeit there are numerous explanations for the lack of association including 
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Left Atrial Emptying Fraction as a Predictor of Mortality
LAEF was strongly correlated with mortality in our study on univariable and multivariable 
analyses. This was an unexpected finding and LAEF has not been extensively studied within 
this population. LAEF has been shown to associate with adverse cardiovascular events in the 
general population (35), elderly (36) and in patients with heart failure (37,38). Furthermore, 
there is extensive evidence correlating left atrial volumes with mortality, including in patients 
on haemodialysis (21,39). It is not clear if left atrial impairment is directly involved in the 
pathophysiology of the excess mortality, or if it is a surrogate marker, perhaps for volume 
overload or left ventricular diastolic dysfunction (40,41).
CMR in the assessment of suitability for transplant 
Renal transplantation, where appropriate, is the optimal treatment for patients with ESKD. 
However, transplants are a limited resource and have potential to cause some patients net 
harm due to the risks of surgery and long-term immunosuppression. Cardiovascular 
assessment (albeit to varying degrees) is standard practice in pre-transplant assessment and 
is recommended by international guidelines (42). However, the evidence supporting this 
practice is scant and so it is becoming increasingly controversial (43). We hypothesised that 
LV-GLS on CMR may be helpful for cardiovascular risk assessment when considering renal 
transplant suitability. LV-GLS significantly associated with mortality in the multivariable model, 
even when future renal transplantation was accounted for. However, the overwhelming 
survival benefit of renal transplantation was evident across all quartiles of LV-GLS (Figure 3), 
suggesting that there is no LV-GLS too poor (or too good) for a patient to reap survival benefit 
from a transplant, if not otherwise contraindicated. Regression of myocardial fibrosis following 
kidney transplant may account for part of this improved survival (7,44).  This retrospective 
observation will be heavily biased due to selection bias and immortal time bias, but as 
randomised controlled trials assessing this will never be ethically feasible, we feel the present 
data are sufficient to say that LV-GLS is unlikely to be helpful when assessing the majority of 
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has not been investigated and advances in free breathing cine acquisitions might make this 
feasible.
Limitations
This is a retrospective analysis of pooled studies, albeit at a single centre using consistent 
imaging protocols. The cohort combines patients scanned at both 1.5T and 3T. While the 
influence from field strength on LV-GLS is likely to be negligible (12), we accept there may be 
a small, unquantified difference in cine parameters between the acquisitions from different 
scanners. Inclusion from source studies was incomplete and unquantified for the studies 
published in 2006 (19) and 2010 (21) due to a combination of overlap in participants between 
the 2 studies and inability to retrieve some CMRs from archiving. The nature of the source 
studies has resulted in a younger than expected mean age (54 +/- 12 years) within this cohort 
and an under-representation of older, prevalent dialysis patients. Further studies to confirm 
our findings in different populations of patients with ESKD are required. It was not possible to 
examine non-fatal cardiovascular outcomes as data from historic patients were insufficient to 
allow reliable examination of cardiovascular events. The source data for our primary outcome 
of all-cause mortality are robust, but the data on cause of death were incomplete resulting in 
reduced power to examine of our secondary outcome of cardiovascular mortality. 
Nevertheless, the weaker association between LV-GLS and cardiovascular mortality, as 
opposed to all-cause mortality, is surprising given the cardio-centric nature of LV-GLS and 
warrants further study. It is plausible that reduced functional myocardial reserve in ESKD 
would impair the ability to recover from other critical illness, such as severe infection, but we 
accept that any future interventional trials targeting LV-GLS as a surrogate marker would be 
expected to address cardiovascular mortality and events. Previous studies examining LV-GLS 
by echocardiography have found associations with all-cause mortality(17,29) and 
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CONCLUSION
In this cohort of patients with ESKD, LV-GLS and LAEF were associated with all-cause 
mortality, independent of baseline clinical variables and future renal transplantation. 
Conversely, conventional imaging biomarkers, such as LVMI and LVEF, did not associate with 
mortality. Using LV-GLS, instead of LVEF, to diagnose cardiac dysfunction in patients with 
ESKD could result in a major advance in our understanding of cardiovascular disease in ESKD 
and may be a more relevant measure in this population. Despite this, the survival benefit of 
renal transplantation was evident across all quartiles of LV-GLS, suggesting that in the 
absence of other contraindications to renal transplant, LV-GLS is unlikely to be helpful when 
assessing patients’ suitability for renal transplantation. Further studies are warranted to 
explore the potential role of LV-GLS as a sample enrichment tool and surrogate outcome 
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Tables and Figures








Age, years (mean (SD)) 54 (+/- 12) 51.2 (+/- 11.7) 56.2 (+/- 12.2) 0.005
Gender, male (n (%)) 133 (62%) 62 (62%) 71 (62%) 0.97
Body mass index (median, 
(IQR)), kg/m2
25.6 (22.4-30.1 25.0 (22.2-29.2) 26.6 (22.4-31.6) 0.06
Diabetes Mellitus (n, (%)) 65 (30%) 22 (22%) 43 (37%) 0.01
Previous myocardial infarction 
(n (%))
32 (15%) 14 (14%) 18 (16%) 0.73
Heart failure (n, (%)) 2 (1%) 1 (1%) 1 (1%) 0.92
Primary Renal Diagnosis
N, (%)
Diabetes Mellitus 48 (22%) 15 (15%) 33 (27%)
Glomerulonephritis 44 (20%) 25 (25%) 19 (17%)
Hypertension / Renal vascular 
disease
18 (8%) 8 (8%) 10 (9%)
Polycystic kidney disease 23 (11%) 13 (13%) 10 (9%)
Pyelonephritis 19 (9%) 9 (9%) 10 (9%)
Unknown 32 (15%) 18 (18%) 14 (12%)
Other (defined) 31 (14%) 12 (12%) 19 (17%) 0.01
CKD status at time of CMR 
N, (%)
Haemodialysis 136 (63%) 72 (72%) 64 (56%)
Peritoneal dialysis 37 (17%) 8 (8%) 29 (25%)
Functioning transplant 8 (4%) 5 (5%) 3 (3%)
CKD stage 5 (pre-dialysis) 34 (16%) 15 (15%) 19 (17%)
Previous renal transplant (non-
functioning)
26 (12%) 15 (15%) 11 (10%) 0.04
RRT vintage at time of CMR 
(median, years (IQR))
1.7 (0.6-4.6) 2.1 (0.6-5.3) 1.3 (0.6-4.3) 0.37
Presented as: mean +/- standard deviation (SD), or median and interquartile range (IQR).
Abbreviations: CKD = chronic kidney disease; CMR = Cardiovascular magnetic resonance 
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Median IQR Median IQR Median IQR
LVMI (g/m2) 70.2 56.4, 84.8
LV-EDVI (ml/m2) 82.7 67.3, 101.2




LVEF (%) 64.7 58.5, 70.0
LV-GLS (%) -15.3 -17.24, -13.6
LV-GRS (%) 24.9 21.1, 29.6
LV-GCS (%) -16.0 -17.8, -13.8
RV-GLS (%) -21.1 -21.1, -17.7 -22.1 -18.39, -20.7 -20.7 -23.3, -16.5 0.008
RV-GRS (%) 44.2 34.4, 56.0 48.7 36.0, 60.8, 42.8 33.1, 53.7 0.05
LAVI min (ml/ m2) 14.0 9.9, 20.6 13.1 8.8, 18.4 15.0 11.2, 23.1 0.002
LAVI max (ml/ m2) 33.6 26.1, 45.9
LAEF (%) 57.5 50.1, 65.1 62.6 55.8, 67.6 54.3 47.1, 60.7 0.001
RAVI min (ml/ m2) 16.7 11.9, 22.8
RAVI max (ml/ 
m2)
33.5 26.7, 43.0
RAEF (%) 48.3 41.3, 58.3
Presented as median and interquartile range (IQR). P-value refers to Mann-Whitney U test comparing baseline cardiovascular MRI parameters for 
alive versus dead. For simplicity, only those variables for which a statistically significant difference with a p value <0.05 are presented.
Abbreviations:
LVMI = left ventricular mass index
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LV-ESVI = left ventricular end systolic volume index
LVM/LVEDV = ratio of left ventricular mass to left ventricular end diastolic volume
LVEF = left ventricular ejection fraction
LV-GLS = left ventricular global longitudinal strain
LV-GRS = left ventricular global radial strain
LV-GCS = left ventricular global circumferential strain
RV-GLS = right ventricular global longitudinal strain
RV-GRS = right ventricular global radial strain
LAVI min = minimum left atrial volume index
LAVI max = maximum left atrial volume index
LAEF = left atrial emptying fraction
RAVI min = minimum right atrial volume index
RAVI max = maximum right atrial volume index
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Table 3. Association between clinical and CMR parameters and all-cause mortality (Cox 
Proportional Hazards Model)
Univariable Multivariable
HR CI P-value HR CI P-value
Sex 
(female)
1.14 0.79-1.67 0.48 1.43 0.95-2.17 0.09
Age 1.04 1.02-1.06 <0.001 1.04 1.02-1.05 <0.001
























LVEF (%) 0.99 0.97-1.01 0.18
LVGLS 
(%)
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LAEF (%) 0.97 0.95-0.99 0.001 0.98 0.96-1.00 0.03






RAEF (%) 1.00 0.99-1.02 0.75
*time dependent covariate
The multivariable model was created using pre-specified clinical variables including sex, age, 
diabetes mellitus, previous myocardial infarction, heart failure and future renal transplantation, 
combined with CMR parameters that significantly associated with mortality on univariable 
analysis. Backwards stepwise elimination (Wald’s) was used to select the optimal variables in 
the final model displayed here. 
Abbreviations:
LVMI = left ventricular mass index
LV-EDVI = left ventricular end diastolic volume index
LV-ESVI = left ventricular end systolic volume index
LVM/LVEDV = ratio of left ventricular mass to left ventricular end diastolic volume
LVEF = left ventricular ejection fraction
LV-GLS = left ventricular global longitudinal strain
LV-GRS = left ventricular global radial strain
LV-GCS = left ventricular global circumferential strain
RV-GLS = right ventricular global longitudinal strain
RV-GRS = right ventricular global radial strain
LAVI min = minimum left atrial volume index
LAVI max = maximum left atrial volume index
LAEF = left atrial emptying fraction
RAVI min = minimum right atrial volume index
RAVI max = maximum right atrial volume index
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FIGURE 1: Representative images showing 2D global longitudinal strain derivation using 
Cvi42 software (version 5.10, Circle Cardiovascular, Canada). Panels show horizontal long 
axis view at diastole (A) and systole (B) and vertical long axis views at diastole (C) and systole 
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FIGURE 2: Kaplan-Meier Curves of All-Cause Mortality by quartiles of: A) peak left ventricular 
global longitudinal strain (LV-GLS) (%), B) left atrial emptying fraction (LAEF) (%). Compared 
to the best quartile of LV-GLS, participants in the worst quartile had significantly poorer 
outcomes (log rank test p=0.03) with no difference between the other quartiles, For LAEF, the 
first quartile had significantly worse survival compared to participants in the 3rd and 4th 
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FIGURE 3: Kaplan-Meier curves of all-cause mortality comparing participants who did and did 
not receive a renal transplant during follow-up for each quartile of left ventricular global 
longitudinal strain (LV-GLS). Survival benefit of renal transplantation was most marked in 
those in the best quartile of LV-GLS but was still significant in participants within the worst 
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Kaplan-Meier curves of all-cause mortality comparing participants who did and did not receive a renal 
transplant during follow-up for each quartile of left atrial emptying fraction (LAEF)). Survival benefit of renal 
transplantation was present, and of similar magnitude, across all quartiles of LAEF (log rank test p<0.001). 
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